<H1>Chapter DOI: 10.1007/978-1-60327-829-4_16<br/>Cited-By Count: 2</H1><table border="1" width="30%"><tr><td>Total References</td><td>117</td></tr><tr><td>Springer references</td><td>2</td></tr><tr><td>Non Springer references</td><td>115</td></tr><tr><td>BibStructured Count</td><td width="10%">117</td></tr><tr><td>BibUnstructured Count</td><td width="10%">0</td></tr><tr><td>DOI already available in SpringerLink</td><td>0</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>66</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>1</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>2</td></tr><tr><td>DOI Obtained For Non Springer</td><td>65</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>67</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>59</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1_16</td><td>BibArticle</td><td>Hamel E, Covell DG. Antimitotic peptides and depsipeptides. Curr Med Chem Anticancer Agents 2002;2:19&#8211;53.</td><td><a href=http://dx.doi.org/10.2174/1568011023354263>10.2174/1568011023354263</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, VolumeID, ArticleTitle, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR2_16</td><td>BibArticle</td><td>Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2002;2:1&#8211;17.</td><td><a href=http://dx.doi.org/10.2174/1568011023354290>10.2174/1568011023354290</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, VolumeID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR3_16</td><td>BibArticle</td><td>Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253&#8211;65.</td><td><a href=http://dx.doi.org/10.1038/nrc1317>10.1038/nrc1317</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_2, Year, Author_FamilyName_1, VolumeID, FirstPage</td><td>CrossRef</td></tr><tr><td>CR4_16</td><td>BibArticle</td><td>Jimenez-Barbero J, Amat-Guerri F, Snyder JP. The solid state, solution and tubulin-bound conformations of agents that promote microtubule stabilization. Curr Med Chem Anticancer Agents 2002;2(1):91&#8211;122.</td><td><a href=http://dx.doi.org/10.2174/1568011023354416>10.2174/1568011023354416</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_2, Author_FamilyName_1, VolumeID, FirstPage, IssueID</td><td>CrossRef</td></tr><tr><td>CR5_16</td><td>BibArticle</td><td>Desai A, Mitchison TJ. Microtubule polymerization dynamics. Annu Rev Cell Dev Biol 1997;13:83&#8211;117.</td><td><a href=http://dx.doi.org/10.1146/annurev.cellbio.13.1.83>10.1146/annurev.cellbio.13.1.83</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, VolumeID, FirstPage, Author_FamilyName_2, ArticleTitle, Year</td><td>CrossRef</td></tr><tr><td>CR6_16</td><td>BibArticle</td><td>Oakley BR. An abundance of tubulins. Trends Cell Biol 2000;10:537&#8211;42.</td><td><a href=http://dx.doi.org/10.1016/S0962-8924(00)01857-2>10.1016/S0962-8924(00)01857-2</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, VolumeID, Author_FamilyName_1, Year, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR7_16</td><td>BibArticle</td><td>Sharp DJ, Rogers GC, Scholey JM. Microtubule motors in mitosis. Nature 2000;407:41&#8211;7.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR8_16</td><td>BibArticle</td><td>Calvert PM, O&#8217;Neill V, Twelves C, et al. A phase I clinical and pharmacokinetic study of EPO906 (Epothilone B), given every three weeks, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2001;20:A429.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR9_16</td><td>BibChapter</td><td>Wilson L, Jordan MA. Pharmacological probes of microtubule function. In: Hyams J, Lloyd C, editors. Microtubules. New York: Wiley; 1994. p. 59&#8211;84.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR10_16</td><td>BibBook</td><td>Jordan MA, Wilson L. The use of drugs to study the role of microtubule assembly dynamics in living cells, Molecular motors and the cytoskeleton. Methods Enzymol, vol. 298. 1998. p. 252&#8211;76.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1016/S0076-6879(98)98024-7>10.1016/S0076-6879(98)98024-7</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, Year, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR11_16</td><td>BibArticle</td><td>Lobert S, Correia J. Energetics of vinca alkaloid interactions with tubulin. Methods Enzymol 2000;323:77&#8211;103.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1016/S0076-6879(00)23362-4>10.1016/S0076-6879(00)23362-4</a></td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, Year, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR12_16</td><td>BibArticle</td><td>Bai RB, Pettit GR, Hamel E. Dolastatin 10. a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol 1990;39:1941&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR13_16</td><td>BibArticle</td><td>Bai RB, Pettit GR, Hamel E. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem 1990;265:17141&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR14_16</td><td>BibArticle</td><td>Wilson L, Jordan MA, Morse A, Margolis RL. Interaction of vinblastine with steady-state microtubules in vitro. J Mol Biol 1982;159:129&#8211;49.</td><td><a href=http://dx.doi.org/10.1016/0022-2836(82)90035-3>10.1016/0022-2836(82)90035-3</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, ArticleTitle, Year, Author_FamilyName_1, VolumeID</td><td>CrossRef</td></tr><tr><td>CR15_16</td><td>BibArticle</td><td>Correia JJ, Lobert S. Physiochemical aspects of tubulin-interacting antimitotic drugs. Curr Pharm Des 2001;7(13):1213&#8211;28.</td><td><a href=http://dx.doi.org/10.2174/1381612013397438>10.2174/1381612013397438</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, Author_FamilyName_2, ArticleTitle, IssueID, FirstPage, VolumeID, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR16_16</td><td>BibArticle</td><td>Na GC, Timasheff SN. Thermodynamic linkage between tubulin self-association and the binding of vinblastine. Biochemistry 1980;19(7):1347&#8211;54.</td><td><a href=http://dx.doi.org/10.1021/bi00548a014>10.1021/bi00548a014</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, Author_FamilyName_2, ArticleTitle, IssueID, JournalTitle, VolumeID, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR17_16</td><td>BibArticle</td><td>Jordan MA, Margolis RL, Himes RH, Wilson L. Identification of a distinct class of vinblastine binding sites on microtubules. J Mol Biol 1986;187:61&#8211;73.</td><td><a href=http://dx.doi.org/10.1016/0022-2836(86)90406-7>10.1016/0022-2836(86)90406-7</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_1, FirstPage, Author_FamilyName_2, ArticleTitle, Year</td><td>CrossRef</td></tr><tr><td>CR18_16</td><td>BibArticle</td><td>Singer WD, Jordan MA, Wilson L, Himes RH. Binding of vinblastine to stabilized microtubules. Mol Pharmacol 1989;36(3):366&#8211;70.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR19_16</td><td>BibArticle</td><td>Panda D, Jordan MA, Chin K, Wilson L. Differential effects of vinblastine on polymerization and dynamics at opposite microtubule ends. J Biol Chem 1996;271:29807&#8211;12.</td><td><a href=http://dx.doi.org/10.1074/jbc.271.47.29807>10.1074/jbc.271.47.29807</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_2, Year, Author_FamilyName_1, VolumeID, FirstPage</td><td>CrossRef</td></tr><tr><td>CR20_16</td><td>BibArticle</td><td>Panda D, Miller H, Wilson L. Determination of the size and chemical nature of the stabilizing cap at microtubule ends using modulators of polymerization dynamics. Biochemistry 2002;41:1609&#8211;17.</td><td><a href=http://dx.doi.org/10.1021/bi011767m>10.1021/bi011767m</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, VolumeID, JournalTitle, Year, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR21_16</td><td>BibArticle</td><td>Hastie SB. Interactions of colchicine with tubulin. Pharmacol Ther 1991;512:377&#8211;401.</td><td><a href=http://dx.doi.org/10.1016/0163-7258(91)90067-V>10.1016/0163-7258(91)90067-V</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, VolumeID, Author_FamilyName_1, Year, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR22_16</td><td>BibArticle</td><td>Sternlicht H, Ringel I. Colchicine inhibition of microtubule assembly via copolymer formations. J Biol Chem 1979;254:10540&#8211;50.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR23_16</td><td>BibArticle</td><td>Sternlicht H, Ringel I, Szasz J. Theory for modelling the copolymerization of tubulin and tubulin-colchicine complex. Biophys J 1983;42:255&#8211;67.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR24_16</td><td>BibArticle</td><td>Farrell KW, Wilson L. The differential kinetic stabilization of opposite microtubule ends by tubulin&#8211;colchicine complexes. Biochemistry 1984;23:3741&#8211;8.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR25_16</td><td>BibArticle</td><td>Skoufias D, Wilson L. Mechanism of inhibition of microtubule polymerization by colchicine: inhibitory potencies of unliganded colchicine and tubulin&#8211;colchicine complexes. Biochemistry 1992;31:738&#8211;46.</td><td><a href=http://dx.doi.org/10.1021/bi00118a015>10.1021/bi00118a015</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, VolumeID, JournalTitle, Author_FamilyName_1, Year, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR26_16</td><td>BibArticle</td><td>Margolis RL, Rauch CT, Wilson L. Mechanism of colchicine dimer addition to microtubule ends: implications for the microtubule polymerization mechanism. Biochemistry 1980;19:5550&#8211;7.</td><td><a href=http://dx.doi.org/10.1021/bi00565a014>10.1021/bi00565a014</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, JournalTitle, VolumeID, Author_FamilyName_1, Year, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR27_16</td><td>BibArticle</td><td>Wilson L, Farrell KW. Kinetics and steady-state dynamics of tubulin addition and loss at opposite microtubule ends: the mechanism of action of colchicine. Ann N Y Acad Sci 1986;466:690&#8211;708.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1111/j.1749-6632.1986.tb38452.x>10.1111/j.1749-6632.1986.tb38452.x</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, Year, Author_FamilyName_1, VolumeID, FirstPage</td><td>CrossRef</td></tr><tr><td>CR28_16</td><td>BibArticle</td><td>Panda D, Goode BL, Feinstein SC, Wilson L. Kinetic stabilization of microtubule dynamics at steady state by tau and microtubule-binding domains of tau. Biochemistry 1995;34:11117&#8211;27.</td><td><a href=http://dx.doi.org/10.1021/bi00035a017>10.1021/bi00035a017</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, Author_FamilyName_2, ArticleTitle, FirstPage, Author_FamilyName_1, JournalTitle, VolumeID</td><td>CrossRef</td></tr><tr><td>CR29_16</td><td>BibArticle</td><td>Jordan A, Hadfield JA, Lawrence NJ, et al. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev 1998;18:259&#8211;96.</td><td><a href=http://dx.doi.org/10.1002/(SICI)1098-1128(199807)18:4%3C259::AID-MED3%3E3.3.CO;2-T>10.1002/(SICI)1098-1128(199807)18:4%3C259::AID-MED3%3E3.3.CO;2-T</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, ArticleTitle, Author_FamilyName_2, FirstPage, VolumeID, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR30_16</td><td>BibArticle</td><td>Pettit GR, Cragg GM, Singh SB. Antineoplastic agents, 122. Constituents of<Emphasis Type="Italic">Combretum caffrum</Emphasis>. J Nat Prod 1987;50:386&#8211;91.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR31_16</td><td>BibArticle</td><td>Tozer GM, Kanthou C, Parkins CS, et al. The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 2002;83:21&#8211;38.</td><td><a href=http://dx.doi.org/10.1046/j.1365-2613.2002.00211.x>10.1046/j.1365-2613.2002.00211.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, VolumeID, FirstPage, ArticleTitle, Author_FamilyName_2, Year</td><td>CrossRef</td></tr><tr><td>CR32_16</td><td>BibArticle</td><td>Pettit GR, Temple Jr C, Narayanan VL, et al. Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des 1995;10:299&#8211;309.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR33_16</td><td>BibArticle</td><td>Dark GG, Hill SA, Prise VE, et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997;57:1829&#8211;34.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR34_16</td><td>BibArticle</td><td>Ahmed B, Van Eijk LI, Bouma-Ter Steege JC, et al. Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity. Int J Cancer 2003;105:20&#8211;5.</td><td><a href=http://dx.doi.org/10.1002/ijc.11010>10.1002/ijc.11010</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Year, Author_FamilyName_1, VolumeID, FirstPage</td><td>CrossRef</td></tr><tr><td>CR35_16</td><td>BibArticle</td><td>Schumacher G, Neuhaus P. The physiological estrogen metabolite 2-methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors. J Cancer Res Clin Oncol 2001;127:405&#8211;10.</td><td><a href=http://dx.doi.org/10.1007/s004320000233>10.1007/s004320000233</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, ArticleTitle, Author_FamilyName_2, FirstPage, VolumeID, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR36_16</td><td>BibArticle</td><td>D&#8217;Amato RJ, Lin CM, Flynn E, et al. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci U S A 1994;91:3964&#8211;8.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR37_16</td><td>BibArticle</td><td>Fotsis T, Zhang Y, Pepper MS, et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994;368:237&#8211;9.</td><td><a href=http://dx.doi.org/10.1038/368237a0>10.1038/368237a0</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, JournalTitle, VolumeID, Author_FamilyName_1, Year, Author_FamilyName_2, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR38_16</td><td>BibArticle</td><td>de Ines C, Leynadier D, Barasoain I, et al. Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7, 8-dihydropteridine antitumor drug, CI 980, and by its chiral isomer, NSC 613863. Cancer Res 1994;54:75&#8211;84.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR39_16</td><td>BibArticle</td><td>Waud WR, Leopold WR, Elliott WL, et al. Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenyl-pyrido [3,4-b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate (NSC 370147) against selected tumor systems in culture and in mice. Cancer Res 1990;50:3239&#8211;44.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR40_16</td><td>BibArticle</td><td>Verdier-Pinard P, Kepler JA, Pettit GR, Hamel E. Sustained intracellular retention of dolastatin 10 causes its potent antimitotic activity. Mol Pharmacol 2000;57:180&#8211;7.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR41_16</td><td>BibArticle</td><td>Singer WD, Hersh RT, Himes RH. Effect of solution variables on the binding of vinblastine to tubulin. Biochem Pharmacol 1988;37:2691&#8211;6.</td><td><a href=http://dx.doi.org/10.1016/0006-2952(88)90264-X>10.1016/0006-2952(88)90264-X</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_1, FirstPage, ArticleTitle, Author_FamilyName_2, Year</td><td>CrossRef</td></tr><tr><td>CR42_16</td><td>BibArticle</td><td>Bai R, Taylor GF, Schmidt JM, Williams MD, Kepler JA, Pettit GR, et al. Interaction of dolastatin 10 with tubulin: Induction of aggregation and binding and dissociation reactions. Mol Pharmacol 1995;47:965&#8211;76.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR43_16</td><td>BibArticle</td><td>Safa AR, Hamel E, Felsted RL. Photoaffinity labeling of tubulin subunits with a photoactive analogue of vinblastine. Biochemistry 1987;26:97&#8211;102.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR44_16</td><td>BibArticle</td><td>Bai RL, Pettit GR, Hamel E. Structure-activity studies with chiral isomers and with segments of the antimitotic marine peptide dolastatin 10. Biochem Pharmacol 1990;40:1859&#8211;64.</td><td><a href=http://dx.doi.org/10.1016/0006-2952(90)90367-T>10.1016/0006-2952(90)90367-T</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, VolumeID, Year, ArticleTitle, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR45_16</td><td>BibArticle</td><td>Bai R, Roach MC, Jayaram SK, et al. Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin. Correlation with cytotoxicity. Biochem Pharmacol 1993;45:1503&#8211;15.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR46_16</td><td>BibArticle</td><td>Pettit GR, Srirangam JK, Barkoczy J, et al. Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications. Anticancer Drug Des 1995;10:529&#8211;44.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR47_16</td><td>BibArticle</td><td>Li Y, Kobayashi H, Hashimoto Y, et al. Interaction of marine toxin dolastatin 10 with porcine brain tubulin: competitive inhibition of rhizoxin and phomopsin A binding. Chem Biol Interact 1994;93:175&#8211;83.</td><td><a href=http://dx.doi.org/10.1016/0009-2797(94)90018-3>10.1016/0009-2797(94)90018-3</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, VolumeID, Author_FamilyName_1, Year, ArticleTitle, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR48_16</td><td>BibArticle</td><td>Otani M, Natsume T, Watanabe JI, et al. TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death. Jpn J Cancer Res 2000;91:837&#8211;44.</td><td><a href=http://dx.doi.org/10.1111/j.1349-7006.2000.tb01022.x>10.1111/j.1349-7006.2000.tb01022.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, VolumeID, Author_FamilyName_1, Year, Author_FamilyName_2, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR49_16</td><td>BibArticle</td><td>Natsume T, Watanabe J, Tamaoki S, et al. Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin. Jpn J Cancer Res 2000;91:737&#8211;47.</td><td><a href=http://dx.doi.org/10.1111/j.1349-7006.2000.tb01007.x>10.1111/j.1349-7006.2000.tb01007.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_1, FirstPage, Author_FamilyName_2, ArticleTitle, Year</td><td>CrossRef</td></tr><tr><td>CR50_16</td><td>BibArticle</td><td>Wani MC, Taylor HL, Wall ME, Coggan P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from<Emphasis Type="Italic">Taxus brevifolia</Emphasis>. J Am Chem Soc 1971;93:2325&#8211;7.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR51_16</td><td>BibArticle</td><td>Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665&#8211;7.</td><td><a href=http://dx.doi.org/10.1038/277665a0>10.1038/277665a0</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, JournalTitle, VolumeID, Author_FamilyName_1, Year, ArticleTitle, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR52_16</td><td>BibArticle</td><td>Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A 1980;77:1561&#8211;5.</td><td><a href=http://dx.doi.org/10.1073/pnas.77.3.1561>10.1073/pnas.77.3.1561</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, VolumeID, Author_FamilyName_1, Year, ArticleTitle, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR53_16</td><td>BibArticle</td><td>Schiff PB, Horwitz SB. Taxol assembles tubulin in the absence of exogenous guanosine 5&#8242;-triphosphate or microtubule-associated proteins. Biochemistry 1981;20:3247&#8211;52.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR54_16</td><td>BibArticle</td><td>Diaz JF, Valpuesta JM, Chacon P, Diakun G, Andreu JM. Changes in microtubule protofilament number induced by Taxol binding to an easily accessible site. Internal microtubule dynamics. J Biol Chem 1998;273:33803&#8211;10.</td><td><a href=http://dx.doi.org/10.1074/jbc.273.50.33803>10.1074/jbc.273.50.33803</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Year, VolumeID, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR55_16</td><td>BibArticle</td><td>Parness J, Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Cell Biol 1981;91:479&#8211;87.</td><td><a href=http://dx.doi.org/10.1083/jcb.91.2.479>10.1083/jcb.91.2.479</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, VolumeID, Year, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR56_16</td><td>BibArticle</td><td>Rao S, Horwitz SB, Ringel I. Direct photoaffinity labeling of tubulin with taxol. J Natl Cancer Inst 1992;84:785&#8211;8.</td><td><a href=http://dx.doi.org/10.1093/jnci/84.10.785>10.1093/jnci/84.10.785</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, VolumeID, Author_FamilyName_1, Year, Author_FamilyName_2, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR57_16</td><td>BibArticle</td><td>Lowe J, Li H, Downing KH, Nogales E. Refined structure of alpha beta-tubulin at 3.5 &#197; resolution. J Mol Biol 2001;313:1045&#8211;57.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR58_16</td><td>BibArticle</td><td>Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A 1993;90:9552&#8211;6.</td><td><a href=http://dx.doi.org/10.1073/pnas.90.20.9552>10.1073/pnas.90.20.9552</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_1, FirstPage, ArticleTitle, Author_FamilyName_2, Year</td><td>CrossRef</td></tr><tr><td>CR59_16</td><td>BibArticle</td><td>Derry WB, Wilson L, Jordan MA. Substoichiometric binding of taxol suppresses microtubule dynamics. Biochemistry 1995;34:2203&#8211;11.</td><td><a href=http://dx.doi.org/10.1021/bi00007a014>10.1021/bi00007a014</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, VolumeID, JournalTitle, Year, Author_FamilyName_2, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR60_16</td><td>BibArticle</td><td>Chen JG, Horwitz SB. Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. Cancer Res 2002;62:1935&#8211;8.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR61_16</td><td>BibArticle</td><td>Torres K, Horwitz SB. Mechanisms of taxol-induced cell death are concentration dependent. Cancer Res 1998;58:3620&#8211;6.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR62_16</td><td>BibArticle</td><td>Rao S, Krauss NE, Heerding JM, Swindell CS, Ringel I, Orr GA, et al. 3&#8242;-(p-azidobenzamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin. J Biol Chem 1994;269:3132&#8211;4.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR63_16</td><td>BibArticle</td><td>Rao S, Orr GA, Chaudhary AG, Kingston DG, Horwitz SB. Characterization of the taxol binding site on the microtubule. 2-(m-Azidobenzoyl)taxol photolabels a peptide (amino acids 217-231) of beta-tubulin. J Biol Chem 1995;270:20235&#8211;8.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR64_16</td><td>BibArticle</td><td>Orr GA, Rao S, Swindell CS, Kingston DG, Horwitz SB. Photoaffinity labeling approach to map the taxol-binding site on the microtubule. Methods Enzymol 1998;298:238&#8211;52.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1016/S0076-6879(98)98023-5>10.1016/S0076-6879(98)98023-5</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, Author_FamilyName_2, Year</td><td>CrossRef</td></tr><tr><td>CR65_16</td><td>BibArticle</td><td>Rao S, He L, Chakravarty S, Ojima I, Orr GA, Horwitz SB. Characterization of the taxol binding site on the microtubule. Identification of Arg(282) in beta-tubulin as the site of photoincorporation of a 7-benzophenone analogue of taxol. J Biol Chem 1999;274:37990&#8211;4.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR66_16</td><td>BibArticle</td><td>Rao S, Aberg F, Nieves E, Horwitz SB, Orr GA. Identification by mass spectrometry of a new alpha-tubulin isotype expressed in human breast and lung carcinoma cell lines. Biochemistry 2001;40:2096&#8211;103.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR67_16</td><td>BibArticle</td><td>Nogales E, Wolf SG, Downing KH. Structure of the alpha beta tubulin dimer by electron crystallography. Nature 1998;391:199&#8211;203. erratum in: Nature 393:191.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR68_16</td><td>BibArticle</td><td>Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995;55:2325&#8211;33.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR69_16</td><td>BibArticle</td><td>ter Haar E, Kowalski RJ, Hamel E, Lin CM, Longley RE, Gunasekera SP, et al. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. Biochemistry 1996;35:243&#8211;50.</td><td><a href=http://dx.doi.org/10.1021/bi9515127>10.1021/bi9515127</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, Year, JournalTitle, VolumeID, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR70_16</td><td>BibArticle</td><td>He L, Orr GA, Horwitz SB. Novel molecules that interact with microtubules and have functional activity similar to taxol. Drug Discov Today 2001;6:1153&#8211;64.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1016/S1359-6446(01)02038-4>10.1016/S1359-6446(01)02038-4</a></td><td><b>CrossRef-Meta</b></td>
<td>Year, Author_FamilyName_2, FirstPage, Author_FamilyName_1, VolumeID</td><td>CrossRef</td></tr><tr><td>CR71_16</td><td>BibArticle</td><td>Hung DT, Chen J, Schreiber SL. (+)-Discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks taxol binding and results in mitotic arrest. Chem Biol 1996;3:287&#8211;93.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1016/S1074-5521(96)90108-8>10.1016/S1074-5521(96)90108-8</a></td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_1, FirstPage, Author_FamilyName_2, Year</td><td>CrossRef</td></tr><tr><td>CR72_16</td><td>BibArticle</td><td>Kowalski RJ, Giannakakou P, Gunasekera SP, Longley RE, Day BW, Hamel E. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol Pharmacol 1997;52:613&#8211;22.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR73_16</td><td>BibArticle</td><td>Long BH, Carboni JM, Wasserman AJ, Cornell LA, Casazza AM, Jensen PR, et al. Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (taxol). Cancer Res 1998;58:1111&#8211;5.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR74_16</td><td>BibArticle</td><td>Hamel E, Sackett DL, Vourloumis D, Nicolaou KC. The coral-derived natural products eleutherobin and sarcodictyins A and B: effects on the assembly of purified tubulin with and without microtubule-associated proteins and binding at the polymer taxoid site. Biochemistry 1999;38:5490&#8211;8.</td><td><a href=http://dx.doi.org/10.1021/bi983023n>10.1021/bi983023n</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, Year, JournalTitle, VolumeID, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR75_16</td><td>BibArticle</td><td>Mooberry SL, Tien G, Hernandez AH, Plubrukarn A, Davison BS. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents. Cancer Res 1999;59:653&#8211;60.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR76_16</td><td>BibArticle</td><td>Pryor DE, O&#8217;Brate A, Bilcer G, Diaz JF, Wang Y, Kabaki M, et al. The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry 2002;41:9109&#8211;15.</td><td><a href=http://dx.doi.org/10.1021/bi020211b>10.1021/bi020211b</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, FirstPage, JournalTitle, VolumeID, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR77_16</td><td>BibArticle</td><td>Pineda O, Farras J, Maccari L, Manetti F, Botta M, Vilarrasa J. Computational comparison of microtubule-stabilising agents laulimalide and peloruside with taxol and colchicine. Bioorg Med Chem Lett 2004;14:4825&#8211;9.</td><td><a href=http://dx.doi.org/10.1016/j.bmcl.2004.07.053>10.1016/j.bmcl.2004.07.053</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Year, VolumeID, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR78_16</td><td>BibArticle</td><td>Fojo AT, Whang-Peng J, Gottesman MM, Pastan I. Amplification of DNA sequences in human multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci U S A 1985;82:7661&#8211;5.</td><td><a href=http://dx.doi.org/10.1073/pnas.82.22.7661>10.1073/pnas.82.22.7661</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, VolumeID, Author_FamilyName_1, Year, ArticleTitle, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR79_16</td><td>BibArticle</td><td>Hari M, Wang Y, Veeraraghavan S, Cabral F. Mutations in alpha- and beta-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine. Mol Cancer Ther 2003;2:597&#8211;605.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR80_16</td><td>BibArticle</td><td>Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997;272:17118&#8211;25.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR81_16</td><td>BibArticle</td><td>Giannakakou P, Sackett DL, Ward Y, Webster KR, Blagosklonny MV, Fojo T. p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nat Cell Biol 2000;2:709&#8211;17.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR82_16</td><td>BibArticle</td><td>Hari M, Loganzo F, Annable T, Tan X, Musto S, Morilla DB, et al. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules. Mol Cancer Ther 2006;5:270&#8211;8.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR83_16</td><td>BibArticle</td><td>Cabral FR, Brady RC, Schibler MJ. A mechanism of cellular resistance to drugs that interfere with microtubule assembly. Ann N Y Acad Sci 1986;466:745&#8211;56.</td><td><a href=http://dx.doi.org/10.1111/j.1749-6632.1986.tb38456.x>10.1111/j.1749-6632.1986.tb38456.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, VolumeID, FirstPage, ArticleTitle, Author_FamilyName_2, Year</td><td>CrossRef</td></tr><tr><td>CR84_16</td><td>BibArticle</td><td>Cabral F, Barlow SB. Mechanisms by which mammalian cells acquire resistance to drugs that affect microtubule assembly. FASEB J 1989;3:1593&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR85_16</td><td>BibArticle</td><td>Minotti AM, Barlow SB, Cabral F. Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J Biol Chem 1991;266:3987&#8211;94.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR86_16</td><td>BibArticle</td><td>Wilson L, Jordan MA. Microtubule dynamics: taking aim at a moving target. Chem Biol 1995;2:569&#8211;73.</td><td><a href=http://dx.doi.org/10.1016/1074-5521(95)90119-1>10.1016/1074-5521(95)90119-1</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, Author_FamilyName_2, ArticleTitle, FirstPage, Author_FamilyName_1, VolumeID</td><td>CrossRef</td></tr><tr><td>CR87_16</td><td>BibArticle</td><td>Jordan MA, Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998;10:123&#8211;30.</td><td><a href=http://dx.doi.org/10.1016/S0955-0674(98)80095-1>10.1016/S0955-0674(98)80095-1</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, Author_FamilyName_2, ArticleTitle, FirstPage, Author_FamilyName_1, VolumeID</td><td>CrossRef</td></tr><tr><td>CR88_16</td><td>BibArticle</td><td>Goncalves A, Braguer D, Kamath K, Martello L, Briand C, Horwitz S, et al. Resistance to taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci U S A 2001;98:11737&#8211;42.</td><td><a href=http://dx.doi.org/10.1073/pnas.191388598>10.1073/pnas.191388598</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, ArticleTitle, Year, Author_FamilyName_1, VolumeID, FirstPage</td><td>CrossRef</td></tr><tr><td>CR89_16</td><td>BibArticle</td><td>Fojo AT, Menefee M. Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR). Semin Oncol 2005;32:S3&#8211;8.</td><td><a href=http://dx.doi.org/10.1053/j.seminoncol.2005.09.010>10.1053/j.seminoncol.2005.09.010</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_1, ArticleTitle, Author_FamilyName_2, Year</td><td>CrossRef</td></tr><tr><td>CR90_16</td><td>BibArticle</td><td>Jemal A, Siegel R, Ward E, et al. Cancer Statistics, CA Cancer. J Clin 2009;59:225&#8211;49.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR91_16</td><td>BibArticle</td><td>Tannock IF, de Wit R, Berry W, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502&#8211;12.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa040720>10.1056/NEJMoa040720</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_1, FirstPage, ArticleTitle, Year</td><td>CrossRef</td></tr><tr><td>CR92_16</td><td>BibArticle</td><td>Petrylak DP, Tangen CM, Hussain M, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513&#8211;20.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa041318>10.1056/NEJMoa041318</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_2, Year, Author_FamilyName_1, VolumeID, FirstPage</td><td>CrossRef</td></tr><tr><td>CR93_16</td><td>BibArticle</td><td>Dawson N. Epothilones in prostate cancer: review of clinical experience. Ann Oncol 2007;18 Suppl 5:v22&#8211;7.</td><td><a href=http://dx.doi.org/10.1093/annonc/mdm175>10.1093/annonc/mdm175</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, VolumeID, Author_FamilyName_1, Year, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR94_16</td><td>BibArticle</td><td>Lee JJ, Kelly WK. Epothilones: tubulin polymerization as a novel target for prostate cancer therapy. Nat Clin Pract Oncol 2009;6(2):85&#8211;92.</td><td><a href=http://dx.doi.org/10.1038/ncponc1281>10.1038/ncponc1281</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_1, IssueID, FirstPage, ArticleTitle, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR95_16</td><td>BibArticle</td><td>Beardsley EK, Chi KN. Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer. Curr Opin Support Palliat Care 2008;2:161&#8211;6.</td><td><a href=http://dx.doi.org/10.1097/SPC.0b013e32830c48a3>10.1097/SPC.0b013e32830c48a3</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, VolumeID, FirstPage, Author_FamilyName_2, ArticleTitle, Year</td><td>CrossRef</td></tr><tr><td>CR96_16</td><td>BibArticle</td><td>Rivera E, Lee J, Davies A. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Oncologist 2008;13:1207&#8211;23.</td><td><a href=http://dx.doi.org/10.1634/theoncologist.2008-0143>10.1634/theoncologist.2008-0143</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, VolumeID, Author_FamilyName_1, Year, Author_FamilyName_2, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR97_16</td><td>BibArticle</td><td>Sepp-Lorenzino L, Balog A, Su DS, et al. The microtubule-stabilizing agents epothilones A and B and their desoxy-derivatives induce mitotic arrest and apoptosis in human prostate cancer cells. Prostate Cancer Prostatic Dis 1999;2:41&#8211;52.</td><td><a href=http://dx.doi.org/10.1038/sj.pcan.4500282>10.1038/sj.pcan.4500282</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, ArticleTitle, Year, VolumeID, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR98_16</td><td>BibArticle</td><td>O&#8217;Reilly T, McSheehy PM, Wenger F, et al. Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo. Prostate 2005;65:231&#8211;40.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/pros.20289>10.1002/pros.20289</a></td><td><b>CrossRef-Web</b></td>
<td>VolumeID, FirstPage, ArticleTitle, Author_FamilyName_2, Year</td><td>CrossRef</td></tr><tr><td>CR99_16</td><td>BibArticle</td><td>Altmann KH. Recent developments in the chemical biology of epothilones. Curr Pharm Des 2005;11:1595&#8211;613.</td><td><a href=http://dx.doi.org/10.2174/1381612053764715>10.2174/1381612053764715</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, ArticleTitle, FirstPage, VolumeID, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR100_16</td><td>BibArticle</td><td>Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol<Superscript>&#174;</Superscript>). J Biol Chem 1997;272:2534&#8211;41.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR101_16</td><td>BibArticle</td><td>Wartmann M, Altmann KH. The biology and medicinal chemistry of epothilones. Curr Med Chem Anticancer Agents 2002;2:123&#8211;48.</td><td><a href=http://dx.doi.org/10.2174/1568011023354489>10.2174/1568011023354489</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, ArticleTitle, Author_FamilyName_1, VolumeID, FirstPage</td><td>CrossRef</td></tr><tr><td>CR102_16</td><td>BibArticle</td><td>Calvert PM, O&#8217;Neill V, Twelves C, et al. A phase I clinical and pharmacokinetic study of EPO906 (Epothilone B), given every three weeks, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2001;20:A429.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR103_16</td><td>BibArticle</td><td>Rubin EH, Rothermel J, Fisseha T, et al. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J Clin Oncol 2005;23:9120&#8211;9.</td><td><a href=http://dx.doi.org/10.1200/JCO.2005.03.0981>10.1200/JCO.2005.03.0981</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_1, FirstPage, ArticleTitle, Year</td><td>CrossRef</td></tr><tr><td>CR104_16</td><td>BibArticle</td><td>Gadgeel SM, Wozniak A, Boinpally RR, et al. Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clin Cancer Res 2005;11:6233&#8211;9.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-05-0127>10.1158/1078-0432.CCR-05-0127</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, ArticleTitle, FirstPage, VolumeID, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR105_16</td><td>BibArticle</td><td>Aghajanian C, Burris HA, Jones S, et al. Phase I study of the novel epothilone analog Ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol 2007;25:1082&#8211;8.</td><td><a href=http://dx.doi.org/10.1200/JCO.2006.08.7304>10.1200/JCO.2006.08.7304</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, ArticleTitle, Year, Author_FamilyName_1, VolumeID, FirstPage</td><td>CrossRef</td></tr><tr><td>CR106_16</td><td>BibArticle</td><td>Hussain M, Tangen CM, Lara Jr PN, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-na&#239;ve patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 2005;23:8724&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR107_16</td><td>BibArticle</td><td>Galsky MD, Small EJ, Oh WK, et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005;23:1439&#8211;46.</td><td><a href=http://dx.doi.org/10.1200/JCO.2005.09.042>10.1200/JCO.2005.09.042</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Year, Author_FamilyName_1, VolumeID, FirstPage</td><td>CrossRef</td></tr><tr><td>CR108_16</td><td>BibArticle</td><td>Rosenberg JE, Weinberg VK, Kelly WK, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone refractory prostate cancer patients. Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007;110(3):556&#8211;63.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR109_16</td><td>BibArticle</td><td>Wilding G, Chen Y, DiPaola RP, et al. E3803: updated results on phase II study of a weekly schedule of BMS-247550 for patients with castrate refractory prostate cancer (CRPC). J Clin Oncol 2008;26(Suppl):A5070.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR110_16</td><td>BibArticle</td><td>Chi KN, Beardsley EK, Venner PM, et al. A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel. J Clin Oncol 2008;26(15S) May 20 Suppl:516.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR111_16</td><td>BibArticle</td><td>Hussain A, DiPaola RS, Baron AD, et al. Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol 2009;20:492&#8211;7.</td><td><a href=http://dx.doi.org/10.1093/annonc/mdn665>10.1093/annonc/mdn665</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, VolumeID, ArticleTitle, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR112_16</td><td>BibArticle</td><td>Smaletz O, Galsky M, Scher HI, et al. Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. Ann Oncol 2003;14:1518&#8211;24.</td><td><a href=http://dx.doi.org/10.1093/annonc/mdg415>10.1093/annonc/mdg415</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_1, FirstPage, ArticleTitle, Year</td><td>CrossRef</td></tr><tr><td>CR113_16</td><td>BibArticle</td><td>Beer TM, Higano CS, Saleh M, et al. Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Invest New Drugs 2007;25:565&#8211;70.</td><td><a href=http://dx.doi.org/10.1007/s10637-007-9068-1>10.1007/s10637-007-9068-1</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, JournalTitle, VolumeID, Year, ArticleTitle, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR114_16</td><td>BibBook</td><td>Sanofi-aventis. XRP6258 investigator&#8217;s brochure. Antony (France): Sanofi-aventis; 2000.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR115_16</td><td>BibArticle</td><td>Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane administered as a 10 hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009;15(2):723&#8211;30.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR116_16</td><td>BibArticle</td><td>Pivot X, Koralewski P, Hidalgo JL, et al. A multicenter phase II study of XRP6528 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008;19(9):1547&#8211;52.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR117_16</td><td>BibArticle</td><td>De Bono JS, Oudard S, Ozguroglu M, et al. Cabazitaxel or mitosantrone with presdnisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC). ASCO Annual Meeting Proceedings. J Clin Oncol 2010;28:4508.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></table>